PBMs Under Fire at Senate Hearing
Drug Topics
FEBRUARY 17, 2023
Senators lobbed harsh criticisms at pharmacy benefit managers during a legislative hearing.
Fri.Feb 17, 2023
469 
Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies
PharmaVoice
FEBRUARY 17, 2023
Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Patients Can Effectively Manage Type 2 Diabetes With Digital Therapeutics
Drug Topics
FEBRUARY 17, 2023
Two studies found digital therapeutics can help patients manage their type 2 diabetes effectively regardless of race or ethnicity.
Current treatments for cramps aren’t cutting it. Why aren’t there better options?
STAT
FEBRUARY 17, 2023
One day last fall, Kiran’s period cramps became so painful they woke her up from a nap. The 19-year-old took some ibuprofen, but found little relief. “The pain was so bad, it felt like someone was punching me,” said Kiran, who asked to be referred to by only her first name for privacy. It felt “like I was giving birth.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
New Biosimilars for Autoimmune Diseases Poised to Make Waves
Drug Topics
FEBRUARY 17, 2023
The launch of Amgen's adalimumab biosimilar Amjevita was just the start of a wave of biosimilars to treat autoimmune diseases.
American Telemedicine Association announced 12 telehealth innovators challenge finalists
Fierce Healthcare
FEBRUARY 17, 2023
American Telemedicine Association announced 12 telehealth innovators challenge finalists aburky Fri, 02/17/2023 - 11:45
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Despite rare disease market growth, pharma leaders see development obstacles ahead
PharmaVoice
FEBRUARY 17, 2023
Investment in rare disease research is increasing, but a new poll of PharmaVoice readers found that roadblocks remain.
Becerra charges insurer claims of Medicare Advantage pay cuts 'categorically false'
Fierce Healthcare
FEBRUARY 17, 2023
Becerra charges insurer claims of Medicare Advantage pay cuts 'categorically false' rking Fri, 02/17/2023 - 10:13
Opinion: Improving patient safety shouldn’t be a financial calculation
STAT
FEBRUARY 17, 2023
A recent study of medical error published in The New England Journal of Medicine reached a shocking conclusion about patient safety: Nearly a quarter century after a highly publicized Institute of Medicine report on the prevalence of patient harm sparked vows to cut the rate by half in five years , “in-hospital adverse events” remain so common that they affect roughly one in four patients.
Why Traditional Cybersecurity is Failing Healthcare
Fierce Healthcare
FEBRUARY 17, 2023
Why Traditional Cybersecurity is Failing Healthcare jpiatt Fri, 02/17/2023 - 16:24
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
FDA drug dosage optimisation guidelines signal clinical trial reform
Pharmaceutical Technology
FEBRUARY 17, 2023
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The non-binding draft guidance gives insight into the agency’s current outlook and recommendations for standard and expedited programs in oncology.
Apellis wins FDA approval for first geographic atrophy drug
Fierce Pharma
FEBRUARY 17, 2023
Apellis wins FDA approval for first geographic atrophy drug fkansteiner Fri, 02/17/2023 - 18:06
STAT+: FDA approves first treatment for leading cause of blindness in older people
STAT
FEBRUARY 17, 2023
The Food and Drug Administration approved on Friday the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older people. The new drug, called Syfovre, is made by Apellis Pharmaceuticals.
Private brand sales hit record
Drug Store News
FEBRUARY 17, 2023
In 2022, private label sales hit a new record, according to the Private Label Manufacturers Association.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT+: Government watchdog calls for stronger oversight of for-profit research review boards
STAT
FEBRUARY 17, 2023
The federal government needs to boost its oversight of the institutional review boards that approve scientific studies and protect clinical trial participants, especially since more for-profit companies are taking running these reviews, a report from a government watchdog warns. Also known as ethics committees, institutional review boards occupy a crucial, but behind- the-scenes role in ensuring clinical studies are conducted properly.
Just For Men debuts temporary brush-in, wash-out color
Drug Store News
FEBRUARY 17, 2023
Just For Men’s 1-day Beard and Brow Color is a dye-free temporary brush-in and wash-out color.
STAT+: Medicare Advantage membership grows 7% for 2023
STAT
FEBRUARY 17, 2023
Nearly 31.2 million seniors and people with disabilities are now enrolled in a private Medicare plan, known as Medicare Advantage, according to new federal government data analyzed by STAT. That total is 7.1% higher than the 29.1 million people who had a Medicare Advantage plan in 2022. Although that annual growth rate is the lowest since 2016, the private plans now catch roughly half of the entire Medicare population.
Optum study: Accountable Medicare Advantage models produce better outcomes, greater efficiency
Fierce Healthcare
FEBRUARY 17, 2023
Optum study: Accountable Medicare Advantage models produce better outcomes, greater efficiency pminemyer Fri, 02/17/2023 - 13:40
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Enzyme replacement therapy for alpha-mannosidosis gets FDA approval
European Pharmaceutical Review
FEBRUARY 17, 2023
The US Food and Drug Administration (FDA) has approved Lamzede ® (velmanase alfa-tycv) for non-central nervous system manifestations of alpha-mannosidosis (AM) in adult and paediatric patients. AM is an ultra-rare, progressive lysosomal storage disorder caused by deficiency in the enzyme α-mannosidase. Giacomo Chiesi, Head of Chiesi Global Rare Diseases stated that symptoms of the disorder include “impaired hearing, speech and mobility that progress from childhood into adulthood.
Opinion: 5 ways to address the shortage of health care workers
STAT
FEBRUARY 17, 2023
The shortage of health care workers in Maine, where I live and work, is a harbinger for the struggles the rest of the country will increasingly confront to hire and retain the individuals who make up the backbone of health care. Maine’s population is the oldest in the nation and is tied with Vermont as being the most rural state. Maine’s health care workers are also among the oldest in the country, with many practitioners approaching or even exceeding retirement age.
Stemline Therapeutics receives FDA OK for Orserdu
Drug Store News
FEBRUARY 17, 2023
Orserdu (elacestrant) is the first and only treatment specifically indicated for patients with ESR1 Mutations in ER+, HER2- advanced or metastatic breast cancer.
STAT+: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more
STAT
FEBRUARY 17, 2023
Last week there was a change at the top of PhRMA, the trade group representing the drug industry. Novartis CEO Vas Narasimhan became the chair of the board of directors. Narasimhan has been CEO of Novartis since 2018. He sat down with STAT to discuss the industry’s struggles in Washington, the future of Novartis, and whether the deflated biotech sector is still a little overvalued.
There are some tough-love lessons to be learned from the events of the past year
Drug Store News
FEBRUARY 17, 2023
An aging population combined with increasing numbers of people diagnosed with chronic diseases are among the top factors set to influence innovation in the generics drug market in 2023.
Opinion: Another pharma industry flip-flop: Claims about the IRA’s effect on small-molecule versus biologic drugs
STAT
FEBRUARY 17, 2023
The Inflation Reduction Act of 2022 , which includes provisions requiring Medicare to negotiate lower drug prices for some of the United States’ most costly drugs, marks the first time in decades that the pharmaceutical industry has lost a major policy battle. So, as expected, drug corporations are attacking the new law. The industry’s latest red herring ?
Pendulum rolls out proprietary probiotic blend
Drug Store News
FEBRUARY 17, 2023
Metabolic Daily is a proprietary probiotic supplement that looks to improve the metabolization of sugar and carbohydrates, the company said.
STAT+: Ginkgo chief Jason Kelly is chairing a federal biotech advisory group. Is that a conflict of interest?
STAT
FEBRUARY 17, 2023
Ginkgo Bioworks CEO Jason Kelly has spent much of the last decade talking to almost anyone who will listen — investors, journalists, TV presenters, congressional committees — about the importance of biotechnology to the future of, well, just about everything. This year, Kelly will have a chance to advocate more formally. In December, he was named chairman of a new 12-person congressional commission tasked with issuing a set of policy recommendations for how the U.S. governmen
People on the move … Feb. 17
Drug Store News
FEBRUARY 17, 2023
Important personnel changes you should know this week about the Association for Accessible Medicines, Maesa and more.
STAT+: Pharmalittle: Pfizer scraps half of participants in Lyme vaccine trial over quality issues; Ginkgo CEO may have possible conflict of interest
STAT
FEBRUARY 17, 2023
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up. We plan to tackle mounds of paperwork, promenade with the official mascot, catch up on our reading, and hold a listening party with Mrs. Pharmalot (the rotation will include this , this and this ).
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Fierce Pharma
FEBRUARY 17, 2023
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line aliu Fri, 02/17/2023 - 10:17
STAT+: French court hands Novartis and Roche another win in battle over antitrust allegations involving eye drug
STAT
FEBRUARY 17, 2023
A French appeals court has overturned a record fine levied three years ago against Novartis and Roche for allegedly engaging in anti-competitive practices, the second time this month the companies defeated a country’s antitrust authorities. The Autorité de la Concurrence, France’s competition watchdog, had accused Roche and Novartis of abusing their dominant position to sell a drug used to treat age-related macular degeneration to the detriment of an older and cheaper treatmen
Fusion to acquire radiologand therapy for prostate cancer
European Pharmaceutical Review
FEBRUARY 17, 2023
Fusion Pharmaceuticals has announced the acquisition of an investigational new drug (IND) application for an ongoing Phase II trial evaluating the prostate specific membrane antigen (PSMA)-targeted alpha-emitting radiopharmaceutical 225Ac-PSMA I&T. Following closing of the acquisition of RadioMedix’s small molecule, the radiopharmaceutical will be known as FPI-2265. “With more than 250 patients treated with actinium-based radiopharmaceuticals targeting PSMA in investigator sponso
STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn
STAT
FEBRUARY 17, 2023
In the aftermath of the Food and Drug Administration’s Aduhelm debacle , the agency’s neuroscience chief Billy Dunn has another controversial approval decision to make. It will once again test his willingness to apply the FDA’s doctrine of “regulatory flexibility” to a medicine with less-than-convincing clinical data.
Living Up to Its Promise: Can Omnichannel Deliver the ROI Pharma Needs to Keep Investing?
PharmExec
FEBRUARY 17, 2023
Webinar Date/Time: Mon, Mar 13, 2023 11:00 AM EDT
Let's personalize your content